Skip to main content
MLTX
NASDAQ Life Sciences

MoonLake Q3: $498.5M Cash, BLA Acceptance Decision Due by End-November

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$11.61
Mkt Cap
$995.748M
52W Low
$9.46
52W High
$23.29
52W Position info
23% above low
Off High info
50% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

MLTX sits 23% above its 52-week low of $9.46.

Summary

MoonLake reported Q3 2026 results with $498.5 million in cash and a runway to mid-2028, and said the FDA will decide by end-November whether to accept its sonelokimab BLA for review, with a PDUFA date and Priority Review decision by mid-December.


Key Events · Earnings and Guidance · MLTX

  • Q3 Cash Position and Runway

    Ended September 30, 2026 with $498.5 million in cash, cash equivalents and short-term marketable debt securities, down from $537 million at June 30; management expects funding to mid-2028.

  • R&D Jump on BLA Milestone Accrual

    R&D expense rose to $68.9 million from $50.2 million, an $18.7 million increase primarily from accrued milestone license fees tied to the expected BLA acceptance. Net loss was $79.5 million, or $0.93 per share.

  • FDA Acceptance Decision Due Late November

    BLA for sonelokimab in moderate-to-severe HS was submitted September 30, 2026; a decision on acceptance for review is expected by end-November 2026, with PDUFA date allocation and a Priority Review decision by mid-December 2026.

  • Non-Dilutive Debt Capacity Remains

    Up to $400 million remains available under the Hercules Capital debt facility, alongside the ATM program upsized to $300 million in August 2026.


Analysis · MLTX · Life Sciences

The quarter's headline is the balance sheet and the regulatory clock. MoonLake burned $79.5 million in Q3 and ended September with $498.5 million in cash and short-term securities, which management says funds operations into mid-2028 — past the expected H2 2027 US launch of sonelokimab in hidradenitis suppurativa if approved. R&D jumped to $68.9 million from $50.2 million, driven by an $18.7 million accrual for a milestone license fee tied to the expected BLA acceptance, so part of the higher spend is a one-time regulatory trigger rather than a permanent step-up. The near-term swing factor is the FDA: a decision on whether the BLA is accepted for review is expected by end-November 2026, with a PDUFA date and a Priority Review decision by mid-December. A refusal-to-file or a standard (rather than priority) review would reset the launch timeline; acceptance keeps the H2 2027 launch plan intact. The up-to-$400 million Hercules facility remains undrawn headroom and is non-dilutive, which matters because the ATM was upsized to $300 million in August.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MLTX was trading at $11.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $995.7M. The 52-week trading range was $9.46 to $23.29. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MLTX - Latest Insights

MLTX
Nov 09, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $11.60
Real-time Price: $11.00 info
Change: -$0.600 (-5%) info
Market Cap: $918.301M info
MLTX
Nov 04, 2026, 7:10 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $11.62
Real-time Price: $11.00 info
Change: -$0.620 (-5%) info
Market Cap: $918.301M info
MLTX
Sep 30, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.81
Real-time Price: $11.00 info
Change: -$0.8107 (-7%) info
Market Cap: $918.301M info
MLTX
Aug 10, 2026, 1:21 PM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $17.11
Real-time Price: $11.00 info
Change: -$6.11 (-36%) info
Market Cap: $918.301M info
MLTX
Aug 10, 2026, 7:46 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $16.19
Real-time Price: $11.00 info
Change: -$5.19 (-32%) info
Market Cap: $918.301M info